The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Lock keywords
Exclude keywords
Optional keywords
Cambridge, United Kingdom
101-250 Employees
2010
Based in Cambridge, UK, Kymab, a Sanofi company, is developing novel human antibody-based therapies in a broad range of indications. Our unique platforms generate a vast repertoire of fully-human, species cross-reactive and affinity-matured antibodies against challenging targets. With investment totalling $280m, we are using our antibody platforms to realise new opportunities in therapeutic antibodies and vaccine development. From the Wellcome Trust Sanger Institute’s first spin-out to a leading therapeutic antibody company. Our vision is to be a global biopharmaceutical company, driving the development of therapeutic human antibodies.
+
Featured
Bispecific antibodies
... Bispecific antibodies ...
Shanghai, China
51-100 Employees
2016
We are building a robust pipeline with our integrated Harbour antibody platform, that enable us to develop highly differentiated antibodies against various disease targets with great potency and safety profiles. Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. HBM’s efforts are driven by our vision of delivering “Healthy life · Breakthrough Medicines”. We also provide technology licensing for our proprietary Harbour antibody technologies to accelerate the industry innovation on antibody therapeutics. Our strategic priority is leading next-gen biotherapeutics innovation in global market powered by our proprietary technology platforms and expertise. Harbour Therapeutics focuses on advancing the global portfolio of transformative therapeutics, and Nona Biosciences provides wildly open access to HBM technologies and expertise with an innovative business model to accelerate global biotherapeutic innovation and ultimately benefit patients around the world. Weihao Xu, is the President of Harbour BioMed US and Chief Business Officer.
+
Featured
Bispecific Antibodies
... Bispecific Antibodies-hbm ...
Tübingen, Germany
1-10 Employees
SYNIMMUNE GmbH is a biotechnology company dedicated to the development of innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE GmbH is a spin-off of the Department of Immunology of the University of Tuebingen. SYNIMMUNE GmbH is delighted to announce the signing of a manufacturing service agreement with GenScript ProBio, a highly professional and competent CDMO.
+
Featured
SYNIMMUNE GmbH: Bispecific antibodies
... SYNIMMUNE GmbH: Bispecific antibodies ...
Pfäffikon, Switzerland
11-50 Employees
2017
Together we develop novel treatment options for cancer patients – helping the body to fight cancer.
+
Featured
In what we have been involved already
... BCMA-T cell bispecific antibodies for the treatment of multiple myeloma Klaus Strein was a co-founder of the Swiss biotech startup EngMab and Dr. Erich Hunziker ...
Hayward, United States
11-50 Employees
2017
We are a biotech startup in the San Francisco Bay Area founded in February 2017. Our goal is to close the gap between antibody discovery and therapeutic antibody development by developing the next generation of therapeutic antibodies. We focus on developing complex antibodies with enhanced efficacy, safety, and manufacturability features against difficult-to-treat diseases including cancer, infectious diseases, and CNS diseases, by combining conventional approaches with computer-aided antibody design (CAAD). Our founder and lead scientists have extensive expertise in the fields of therapeutic antibody discovery, lead selection, engineering, humanization, and optimization. We believe in quality-by-design and have established several CAAD-based unique technology platforms for antibody development and are in the process of developing more platforms and therapeutics. Founder, Yue Liu, is a leading scientist with extensive expertise in therapeutic antibody discovery and computer-aided design. Joining Yue, the team is composed of experts in antibody engineering, B-cell cloning, cancer biology, immunology and virology.
+
Featured
AB Studio - Antibody Technology Platform, Bispecific & Trispecific Antibodies
... AB Studio - Antibody Technology Platform, Bispecific & Trispecific Antibodies ...
Plan-les-Ouates, Switzerland
101-250 Employees
1998
After the successful divestment of Emapalumab related activities, we now focus on our bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience.
+
Featured
Beyond bispecific antibodies
... Beyond bispecific antibodies ...
London, United Kingdom
11-50 Employees
2019
NovalGen is an innovative immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer. NovalGen is focused on the development of cutting-edge, proprietary treatments for patients with hematologic malignancies and solid tumors by developing therapeutics that treat cancer using our breakthrough technologies in Bispecific antibodies and beyond. Our mission is to create life-enhancing and curative new treatments for people with cancer. Headquartered in London, UK, NovalGen was formed in 2019. NovalGen is guided by our core set of values. The culture of NovalGen reflects these values and they help guide our decisions. NovalGen’s first pipeline product is a proprietary first in class bispecific T cell engager therapies that can safely harness the immune system to fight a wide range of cancers. We are changing the paradigm of cancer therapy with our immunotherapy technology.
+
Featured
NovalGen – Breakthrough bispecific antibody therapies to treat cancer
... NovalGen is an innovative immuno-oncology company focused on bispecific antibody approaches to fight cancer. ...
Hampton, United States
101-250 Employees
1983
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Celldex, founded in 2004 as a subsidiary of Medarex (Medarex is now a wholly-owned subsidiary of Bristol Myers Squibb), was initially spun out as an independent private company in October 2005 with the asset acquisition of CDX-110 from Alteris Therapeutics, Inc. Young joined Celldex in July 2019 as Senior Vice President and Chief Medical Officer. Crowley joined Celldex in 2009 as Vice President, Clinical Development. Martin joined Celldex in April 2009 as Director of Financial Reporting, Planning and Analysis and most recently served as Vice President, Finance. Pepin joined Celldex in July 2011 as Senior Vice President and Chief Business Officer. Cavanaugh joined Celldex in August 2012 as Vice President of Investor Relations and Corporate Communications. Heath-Chiozzi joined Celldex in October 2017 as Senior Vice President, Regulatory Affairs.
+
Featured
About Us - Celldex Therapeutics
... Dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. ...
Taizhou, China
251-500 Employees
2012
Biointron is a leading high-throughput recombinant antibody/protein expression and discovery service provider. Biointron has delivered tens of thousands of recombinant antibodies for more than 1,500 biotech and pharma companies all over the world. We are committed to advancing the field of biotechnology through innovative research and development – with the ultimate goal of improving human health and well-being. We are a team of hard-working, dedicated individuals who believe that our success is directly tied to our willingness to work tirelessly to achieve our shared goals while constantly innovating and improving. We are on our way towards an IPO on the A-share market. We are fully committed to managing the ethical, societal, and environmental implications that arise from our endeavors. Biointron is firmly grounded in the principles of transparency, sustainability, and community support, which not only inform our daily actions but also guide our long-term strategies. Biointron Insights: Antibody Industry Report (YTD December 2023 Insights, Trends & Analysis) LEARN MORE.
+
Featured
Bispecific Antibody Production
... Bispecific Antibody ...
San Francisco, United States
11-50 Employees
2018
At Soteria Biotherapeutics, we are developing a next generation of bispecific T-cell engagers to treat patients with solid tumor cancers. Our mission is to safely harness the body’s natural immune system to defeat cancer and transform patients’ lives. We are an immuno-oncology company developing a next generation of bispecific T-cell engagers to treat patients with solid tumor cancers. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing. The company was founded in 2018 by Jim Wells, PhD, renowned protein engineer and professor at UC San Francisco, Zachary Hill, PhD, and Alexander Martinko, PhD. Ball was responsible for leading all administrative functions including strategic planning, corporate development, commercial, human resources, legal, finance and IT. Ball led the company’s initial public offering and the cross-functional team responsible for the merger with Vifor, and was a member of the senior team responsible for the launch and commercialization of its lead candidate, patiromer (US brand name Veltassa®). Dani led the Biologics Product Development function at AbbVie (Allergan) and was responsible for all aspects of drug product development for their biologics portfolio.
+
Featured
Technology - Soteria BioTherapeutics
... Technology overview Bispecific antibodies function by recognizing and binding to two different targets. In the case of T-cell engagers, one part of the bispecific binds to the T-cell and another to a target on the tumor cell (tumor antigen) with the goal of activating the T-cell against the ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about the results you have just received for Bispecific Antibody
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 38 |
| Amount of suitable service providers | 21 |
| Average amount of employees | 51-100 |
| Oldest suiting company | 1983 |
| Youngest suiting company | 2019 |
20%
40%
60%
80%
A bispecific antibody (BsAb) is an engineered protein capable of simultaneously binding to two different types of antigens or two different epitopes on the same antigen, which distinguishes it from conventional monoclonal antibodies that are specific to a single antigen. This dual-targeting ability allows bispecific antibodies to enact unique mechanisms of action, such as redirecting immune cells to tumor cells, blocking two pathways simultaneously in a disease process, or cross-linking cells to induce a desired biological response. Their structure typically involves the fusion of variable regions from two different antibodies, creating a hybrid that retains the antigen-binding sites of both parents. This sophisticated design enables the recruitment of immune cells to cancer cells by engaging both a tumor-associated antigen and an immune cell activator, effectively focusing the immune response directly at the site of the tumor. The development and application of bispecific antibodies have significantly impacted therapeutic strategies, particularly in oncology where they offer a promising approach to cancer immunotherapy. By providing a means to overcome resistance to single-targeted therapies and improving the specificity and efficacy of cancer cell targeting, bispecific antibodies represent a powerful tool in the advancement of precision medicine. Their evolving designs and growing clinical applications continue to unlock new potential in the treatment of complex diseases, demonstrating a critical step forward in biotechnological innovation and therapeutic intervention.
1. Enhanced Specificity:
Bispecific antibodies are engineered to recognize two different antigens or two different epitopes on the same antigen. This dual targeting ability enhances their specificity, allowing them to precisely target diseased cells while sparing healthy ones. This is particularly beneficial in cancer therapy, where minimizing damage to healthy tissue is crucial.
2. Dual Action:
By binding to two targets simultaneously, bispecific antibodies can engage multiple mechanisms of action. For example, one part of the molecule can be designed to bind to a cancer cell, while the other part can recruit immune cells to attack the cancer cell. This dual action can lead to more effective treatments compared to traditional monoclonal antibodies that target a single antigen.
3. Reduced Resistance:
The ability of bispecific antibodies to target multiple antigens may reduce the likelihood of resistance developing. In diseases like cancer, where cells can rapidly mutate, targeting multiple pathways can make it harder for the disease to adapt and develop resistance to the treatment.
4. Streamlined Combination Therapy:
Bispecific antibodies can mimic combination therapies by targeting multiple disease pathways with a single molecule. This can simplify treatment regimens, reduce the risk of drug-drug interactions, and potentially improve patient compliance compared to administering multiple separate drugs.
While evaluating the different suppliers make sure to check the following criteria:
1. Production Capabilities
Ensure the supplier has the capability to produce bispecific antibodies at the scale you require, whether for research, clinical trials, or commercial use.
2. Quality Assurance
Check for certifications like ISO or GMP that indicate the supplier adheres to high-quality manufacturing processes. Ask for quality control data and batch-to-batch consistency.
3. Technological Expertise
The supplier should have a solid understanding and experience in recombinant DNA technology, protein engineering, and antibody humanization techniques.
4. Customization Options
Assess the ability of the supplier to customize bispecific antibodies according to your specific needs, including different formats, valencies, and specificities.
5. Purity Levels
High purity levels are crucial for reliable experimental results and patient safety in clinical applications. Verify the purification methods used and the achievable purity percentages.
6. Stability and Storage Conditions
Understand the stability data provided by the supplier, including the recommended storage conditions and shelf life of the bispecific antibodies.
7. Regulatory Compliance
Ensure the supplier has experience with regulatory requirements for the regions where you plan to use or sell the bispecific antibodies, especially if intended for therapeutic use.
8. Cost and Delivery Terms
Compare pricing, including bulk discounts, and review delivery times and conditions. Ensure they align with your project timelines and budget.
9. Customer Support and After-Sale Service
Evaluate the supplier's customer support capabilities, including technical assistance, responsiveness, and the availability of after-sale services.
Bispecific antibodies (BsAbs) are engineered proteins that can simultaneously bind to two different antigens or epitopes. This unique feature has led to their emerging use across various industries, notably in healthcare, biotechnology, and research. In healthcare, BsAbs are predominantly utilized in the development of innovative cancer treatments. They can engage immune cells and direct them to cancer cells, leading to targeted cell killing. This approach has shown promise in enhancing the efficacy of immunotherapy treatments, providing a new avenue for oncology departments and pharmaceutical companies to develop more effective cancer therapies. Within the biotechnology sector, BsAbs are leveraged for drug discovery and development. By binding to two distinct targets, BsAbs facilitate the dual inhibition of disease pathways, which can be significantly more effective than targeting a single pathway. This dual-targeting strategy is particularly useful in diseases where redundancy in signaling pathways can undermine the efficacy of conventional single-targeted therapies. Biotech firms specializing in therapeutic development are increasingly incorporating BsAbs into their R&D pipelines to explore novel treatment options. Research institutions and diagnostic companies are also finding applications for BsAbs in the development of advanced diagnostic tools. By binding to two different biomarkers simultaneously, BsAbs can improve the specificity and sensitivity of diagnostic assays. This is especially valuable in the early detection of diseases, where accurate diagnosis is critical for effective treatment. As such, BsAbs are playing a pivotal role in the evolution of diagnostic methodologies, benefiting both research endeavors and clinical applications. Overall, the versatility of bispecific antibodies is unlocking new possibilities across industries, from enhancing cancer treatment and accelerating drug development to improving disease diagnostics.
Bispecific antibodies (bsAbs), innovative therapeutic agents capable of engaging two different targets simultaneously, have ascended to a high Technology Readiness Level (TRL), predominantly situated between TRL 7 and TRL 9. This advancement is attributed to their successful transition from theoretical design and early-stage development through to clinical trials and, for some, market authorization. The technical rationale underpinning this elevated TRL stems from significant progress in overcoming initial production challenges and demonstrating therapeutic efficacy and safety in human subjects. Early bsAbs faced hurdles related to manufacturing complexities and stability issues, but recent advancements in recombinant DNA technology and protein engineering have streamlined their production, enhancing their stability, specificity, and efficacy. The clinical validation of bsAbs, exemplified by their approval for treating conditions such as cancer and autoimmune diseases, reflects their ability to effectively engage dual targets, offering therapeutic advantages over monospecific antibodies. This includes the capacity to simultaneously block two pathogenic mechanisms or to recruit immune cells to tumor sites, resulting in improved patient outcomes. The progression to high TRLs is a testament to the maturation of bsAbs from conceptual frameworks to tangible, clinically beneficial therapies, underscored by technical advancements in their design, production, and validation.
In the short term, bispecific antibody (BsAb) technology is anticipated to advance through enhanced molecular engineering techniques, leading to the development of antibodies with superior specificity and reduced immunogenicity. These improvements will focus on optimizing antibody formats that are more effective in recruiting immune cells to target tumors and other disease cells. Additionally, there will be a significant emphasis on improving the stability and solubility of BsAbs, facilitating easier manufacturing processes and increasing their shelf life. In the mid-term, the focus will shift towards expanding the therapeutic applications of bispecific antibodies beyond oncology, into autoimmune diseases, infectious diseases, and ophthalmology. This period will witness the integration of artificial intelligence and machine learning in the design and discovery phases, streamlining the identification of novel bispecific constructs with high therapeutic potential. Advances in understanding the complexities of disease mechanisms will enable the design of BsAbs that can engage multiple pathways simultaneously, offering a more holistic approach to treatment. Long-term developments are expected to revolutionize personalized medicine through the advent of patient-specific bispecific antibodies. This will involve leveraging cutting-edge genomic and proteomic technologies to design BsAbs tailored to an individual’s unique disease profile. Furthermore, there will likely be breakthroughs in combining bispecific antibodies with other therapeutic modalities, such as CAR-T cells and targeted drug delivery systems, to create comprehensive, highly effective treatment regimens. The eventual goal is to achieve precise, targeted therapy with minimal side effects, significantly improving patient outcomes across a broad spectrum of diseases.
Some interesting questions that has been asked about the results you have just received for Bispecific Antibody
What are related technologies to Bispecific Antibody?
Based on our calculations related technologies to Bispecific Antibody are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on Bispecific Antibody?
The most represented industries which are working in Bispecific Antibody are Biotechnology, Health Care, Science and Engineering, Professional Services, Financial Services
How does ensun find these Bispecific Antibody Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.
